Mabion SA

Mabion SA maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.3, indicating a low reliance on debt financing. The company holds PLN 47.8 million in cash and equivalents, which is a significant portion of its total assets of PLN 208.3 million. However, its liquidity position is rated as low, and its operating cash flow is negative at PLN -2.3 million, suggesting potential challenges in maintaining short-term liquidity. Profitability metrics for Mabion are mixed. The company reported a gross profit of PLN 33.5 million on revenue of PLN 46.5 million, yielding a gross margin of 72.1%. However, net income was negative at PLN -1.3 million, and return on equity (ROE) was -1.1%, indicating poor capital efficiency. These figures fall below the industry median for ROE and ROA, which are typically positive for biotechnology firms, suggesting underperformance relative to peers. Mabion's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess geographic or product concentration risk. The company's exposure to specific markets or product lines remains opaque, and no material revenue concentration is disclosed. The company's growth trajectory is uncertain. While revenue increased to PLN 46.5 million in the latest period, the net loss and negative operating cash flow suggest operational inefficiencies. Analysts reported a last actual revenue of PLN 69.0 million, which may indicate a discrepancy or a reporting period mismatch. The outlook for the current and next fiscal years is not explicitly provided, but the negative free cash flow of PLN -18.6 million and capital expenditure of PLN -38.0 million suggest a capital-intensive growth strategy. Risk factors for Mabion include its low liquidity and the potential for dilution, although the risk of dilution is currently rated as low. The company has not issued additional shares recently, and no immediate filing-based liquidity or dilution flags were detected. However, the negative net income and operating cash flow could signal underlying financial stress. Recent events include the latest financial filing, which shows a net loss and negative operating cash flow. No significant regulatory or market events were disclosed in the available data. The company's capital expenditure of PLN -38.0 million indicates ongoing investment in infrastructure or R&D, but the source of funding for these expenditures is not specified.